MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/. Date: Wednesday, November 5, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888 ...

Core Insights - PacBio's HiFi sequencing technology has been selected as the primary platform for the Korean Pangenome Reference Project, a significant initiative led by the Korea Disease Control and Prevention Agency and the National Institute of Health [1][3] - The project aims to create the first large-scale, telomere-to-telomere quality reference genomes for the Korean population, contributing to the global Human Pangenome Reference Consortium [2][3] - This initiative is expected to enhance the understanding of population-specific genetic variants, improve insights into unexplained diseases, and support the development of precision diagnostics and therapies [2][3] Company Overview - PacBio is a leading life science technology company that specializes in advanced sequencing solutions, including HiFi long-read sequencing, addressing complex genetic problems across various research applications [5] - The company provides an integrated sequencing solution that combines accuracy, completeness, and resolution across DNA and RNA, marking the first national pangenome initiative to adopt its full technology suite [4][8] Project Details - The Korean Pangenome Project was announced on September 5, 2024, with a goal of sequencing more than 1,000 whole genomes, expanding from a pilot program that involved 200 researchers and academic participants [3] - The project will capture the unique genetic diversity of the Korean population and integrate this data into international reference standards, thereby advancing disease and evolutionary research [3][4]

Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio’s Revio system, powering one of the largest studies of healthy aging to dateMENLO PARK, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long-read sequencing solutions, today announced that the National Institute on Aging’s Long Life Family Study (LLFS) selected PacBio technology to generate comprehensive genomic and epigenomic data from as many as 7,800 participants. The ef ...

Core Viewpoint - PacBio is set to hold its quarterly conference call to discuss its second quarter 2025 financial results on August 7, 2025, at 5:00 pm Eastern Time [1][2]. Company Overview - PacBio (NASDAQ: PACB) is a leading life science technology company that specializes in designing, developing, and manufacturing advanced sequencing solutions aimed at resolving genetically complex problems for scientists and clinical researchers [2]. - The company's product offerings include HiFi long-read sequencing technologies that cater to a wide range of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications [2]. Conference Call Details - The conference call will be accessible via webcast on PacBio's investor website [1]. - Participants can join the call by dialing in, with a toll-free number for domestic calls and an international number provided [2].

Core Viewpoint - Target ALS and PacBio are launching the largest global whole genome sequencing initiative for ALS, utilizing PacBio's HiFi sequencing technology to analyze over 6,000 genomes, aiming to uncover genetic factors related to ALS and make the data freely available to researchers worldwide [1][6]. Group 1: ALS Research Initiative - The initiative is part of the ALS Global Research Initiative (AGRI) and aims to detect structural variants and other genetic features that may contribute to ALS [1][7]. - The data generated will be shared via the Target ALS Data Engine, promoting open access for researchers globally [1][7]. Group 2: Importance of Long-Read Sequencing - ALS is a complex neurodegenerative disease with many unknowns regarding its genetic origins, and long-read sequencing is essential for detecting genetic elements in non-coding regions of the genome [2][4]. - PacBio's HiFi sequencing technology allows for the analysis of DNA fragments ranging from 1,000 to 20,000 base pairs, significantly improving the ability to identify complex genetic regions compared to traditional short-read methods [4][5]. Group 3: Potential Impact on ALS Understanding - The collaboration aims to reveal novel disease mechanisms that are often missed by short-read sequencing, potentially leading to new diagnostic biomarkers and therapeutic targets [5][6][8]. - The initiative is expected to accelerate discoveries that could improve diagnostics and treatment options for ALS patients [6][8]. Group 4: Target ALS and PacBio Overview - Target ALS is a nonprofit organization focused on advancing ALS research and treatment through innovative approaches and collaboration [9]. - PacBio specializes in advanced sequencing solutions, providing technologies that address complex genetic problems across various research applications [10].